|
1
|
Herskovic A, Martz K, al-Sarraf M,
Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L
and Emami B: Combined chemotherapy and radiotherapy compared with
radiotherapy alone in patients with cancer of the esophagus. N Engl
J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cooper JS, Guo MD, Herskovic A, et al:
Chemoradiotherapy of locally advanced esophageal cancer. Long-term
follow-up of a prospective randomized trial (RTOG 85-01). JAMA.
281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ishida K, Ando N, Yamamoto S, Ide H and
Shinoda M: Phase II study of cisplatin and 5-fluorouracil with
concurrent radiotherapy in advanced squamous cell carcinoma of the
esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical
Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 34:615–619.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shi XH, Yao W and Liu T: Late course
accelerated fractionation in radiotherapy of esophageal carcinoma.
Radiother Oncol. 51:21–26. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han C, Yang XR, Gao XS, Zhou DA and Wan J:
Late course accelerated hyperfractionated radiotherapy for
esophageal carcinoma. Chin J Radiat Oncol. 8:1921999.
|
|
6
|
Sheng XF, Mei BD, Chai MZ, Shen XM, Gu HG
and Song MZ: Late course accelerated hyperfractionation
radiotherapy (LCAHR) for middle esophageal carcinoma: clinical
phase III Trial. Chin J Radiat Oncol. 7:86–89. 1998.
|
|
7
|
Zhao KL, Shi XH, Jiang GL and Wang Y:
Late-course accelerated hyperfractionation radiotherapy for
localized esophageal carcinoma. Int J Radiat Oncol Biol Phys.
60:123–129. 2004. View Article : Google Scholar
|
|
8
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial
of combined-modality therapy for esophageal cancer: high-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin Q, Gao XS, Qiao XY, Zhou ZG, Zhang P,
Chen K, Zhao YN and Asaumi J: Phase I trial of escalating-dose
cisplatin with 5-fluorouracil and concurrent radiotherapy in
Chinese patients with esophageal cancer. Acta Med Okayama.
62:37–44. 2008.PubMed/NCBI
|
|
10
|
Gao XS, Qiao XY, Yang XR, Asaumi J, Zhou
ZG, Wang YD, Zhou DA, Wan J, Kuroda M, Kishi K, Kawasaki S and
Hiraki Y: Late course accelerated hyperfractionation radiotherapy
concomitant with cisplatin in patients with esophageal carcinoma.
Oncol Rep. 9:767–772. 2002.
|
|
11
|
Trotti A, Byhardt R, Stetz J, Gwede C,
Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T,
Shipley W and Curran W: Common toxicity criteria: version 2.0. an
improved reference for grading the acute effects of cancer
treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys.
47:13–47. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cox JD, Stetz J and Pajak TF: Toxicity
criteria of the Radiation Therapy Oncology Group (RTOG) and the
European Organization for Research and Treatment of Cancer (EORTC).
Int J Radiat Oncol Biol Phys. 31:1341–1346. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Blum JL, Jones SE, Buzdar AU, LoRusso PM,
Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS and Griffin T:
Multicenter phase II study of capecitabine in paclitaxel-refractory
metastatic breast cancer. J Clin Oncol. 17:485–493. 1999.PubMed/NCBI
|
|
14
|
Shi XH, Wu GD and Liu XW: Comparison of
treatment results between conventional fractionation and
late-course accelerated fractionation for esophageal carcinoma.
Chin J Radiat Oncol. 3:150–153. 1994.
|
|
15
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qiao XY, Zhou ZG, Gao XS, Ma GX and Wang
J: Comparison between conventional fractionation, late-course
accelerated hyperfractionation and external beam combined with
intracavitary radiation in the treatment of locally moderate and
advanced esophageal carcinoma. Chin J Radiat Oncol. 13:261–264.
2004.
|
|
17
|
Qiao XY, Gao XS, Zhou ZG, Wang X, Zhang J,
Zhang P and Yang XR: Retrospective analysis on results of
late-course accelerated hyperfractionation radiotherapy and
conventional fractionation radiotherapy plus brachytherapy for
esophageal carcinoma. Chin J Radiat Oncol. 15:182–184. 2006.
|
|
18
|
Ajani JA: Contributions of chemotherapy in
the treatment of carcinoma of the esophagus: results and
commentary. Semin Oncol. 21:474–482. 1994.PubMed/NCBI
|
|
19
|
Zhao KL, Wang Y and Shi XH: Late course
accelerated hyper-fractionated radiotherapy of upper and middle
thoracic esophageal T2N0M0 carcinoma. Chin J Radiat Oncol.
24:80–82. 2002.PubMed/NCBI
|
|
20
|
Nutting CM, Bedford JL, Cosgrove VP, Tait
DM, Dearnaley DP and Webb S: A comparison of conformal and
intensity-modulated techniques for oesophageal radiotherapy.
Radiother Oncol. 61:157–163. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang J, Han C, Li XN, Gao C, Jia JH, Cai
BN, Zhang X and Xiao AQ: Short-term efficacy of intensity-modulated
radiotherapy on esophageal carcinoma. Chin J Cancer. 28:1138–1142.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valverde CM, Macarulla T, Casado E, Ramos
FJ, Martinelli E and Tabernero J: Novel targets in gastric and
esophageal cancer. Crit Rev Oncol Hematol. 59:128–138. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Taira N, Doihara H, Oota T, Hara F, Shien
T, Takahashi H, Yoshitomi S, Ishibe Y and Shimizu N: Gefitinib, an
epidermal growth factor receptor blockade agent, shows additional
or synergistic effects on the radiosensitivity of esophageal cancer
cells in vitro. Acta Med Okayama. 60:25–34. 2006.
|
|
24
|
Safran H, Gaissert H, Akerman P, Hesketh
PJ, Chen MH, Moore T, Koness J, Graziano S and Wanebo HJ:
Paclitaxel, cisplatin, and concurrent radiation for esophageal
cancer. Cancer Invest. 19:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Brenner B, Ilson DH, Minsky BD, Bains MS,
Tong W, Gonen M and Kelsen DP: Phase I trial of combined-modality
therapy for localized esophageal cancer: escalating doses of
continuous- infusion paclitaxel with cisplatin and concurrent
radiation therapy. J Clin Oncol. 22:45–52. 2004. View Article : Google Scholar
|
|
26
|
Ilson DH, Bains M, Kelsen DP, O’Reilly E,
Karpeh M, Coit D, Rusch V, Gonen M, Wilson K and Minsky BD: Phase I
trial of escalating-dose irinotecan given weekly with cisplatin and
concurrent radiotherapy in locally advanced esophageal cancer. J
Clin Oncol. 21:2926–2932. 2003. View Article : Google Scholar : PubMed/NCBI
|
